Is Ocular Therapeutix, Inc. (OCUL) a Buy, Sell, or Hold?
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$9.7 USD
-$0.18 (-1.82%)
- Volume
- 1.43M
- Average Volume
- 2.92M
- Market Capitalization
- $2.12B
- P/E Ratio
- -6.64
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $16.44
- Year Low
- $6.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.81
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Pravin U. Dugel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | OCUL |
| CUSIP | 67576A100 |
| CIK | 0001393434 |
| Web | https://www.ocutx.com |
| Phone | 781 357 4000 |
| Currency | USD |
| Employees | 325 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 14.81 |
| Quick Ratio | 14.73 |
| Cash Ratio | 13.98 |
Sales & Book Value
| Annual Sales | $51.82M |
| Price / Sales | 40.81 |
| Cash Flow | -1.08 |
| Price / Cash Flow | -8.81 |
| Price / Book | 3.74 |
Price Target and Rating
| Average Stock Price Forecast | $30.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -67.67% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.42 |
| Trailing P/E Ratio | -6.64 |
| PEG Ratio | 0.28 |
| P/E Growth | 0.28 |
| Net Income | $-265.94M |
| Net Margin | -558.24% |
| Pretax Margin | -558.24% |
| Return on Equity | -64.55% |
| Return on Assets | -39.66% |
Financials Score
| AltmanZ Score | 6.11 |
| Piotroski Score | 2.00 |
| Working Capital | 658.31M |
| Total Assets | 732.53M |
| Ebit | -278.87M |
| Market Cap | 2.16B |
| Total Liabilities | 150.96M |
Poll Results
About Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implan ... t in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-09 16:05:00
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
2026-07-01 07:00:00
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
2026-07-01 07:00:00
BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences: 9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 - 11:44 AM EDTPresenter: Peter K.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-22 16:05:00
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company's new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
2026-06-17 23:42:09
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
2026-06-17 10:55:03
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI.
2026-06-17 08:45:00
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-15 16:10:02
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.
Frequently Asked Questions
-
What is the current Ocular Therapeutix, Inc. (OCUL) stock price?
-
Ocular Therapeutix, Inc.(NASDAQ:OCUL) stock price is $9.7 in the last trading session. During the trading session, OCUL stock reached the peak price of $16.44 while $6.23 was the lowest point it dropped to. The percentage change in OCUL stock occurred in the recent session was --1.82% while the dollar amount for the price change in OCUL stock was -$-0.18.
-
OCUL's industry and sector of operation?
-
The NASDAQ listed OCUL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OCUL?
-
Donald Notman Jr. | Chief Operating Officer (Leave of Absence)
Steve Meyers | Chief Commercial Officer
Jason Robins | CFO & Principal Accounting Officer
William S. Slattery Jr. | Vice President of Investor Relations
Jeffrey S. Heier | Chief Scientific Officer -
How many employees does OCUL have?
-
Number of OCUL employees currently stands at 325. OCUL operates from 24 Crosby Drive, Bedford, MA 01730, US.
-
Link for OCUL official website?
-
Official Website of OCUL is: https://www.ocutx.com
-
How do I contact OCUL?
-
OCUL could be contacted at phone #781 357 4000 and can also be accessed through its website. OCUL operates from 24 Crosby Drive, Bedford, MA 01730, US.
-
How many shares of OCUL are traded daily?
-
The average number of OCUL shares traded daily for last 3 months was 2.92M.
-
What is the market cap of OCUL currently?
-
The market value of OCUL currently stands at $2.12B with its latest stock price at $9.7